- Issue price
- ₹1,062per share
- Issue size
- ₹655.37 Cr61,74,051 shares
- Face value
- ₹10per equity share
- Lot size
- 14 sharesMin. ₹14,868 at the upper price
- Anchor biddingFri, 2025
- OpensMon, 2025
- ClosesWed, 2025
- ListingMon, 2025
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue and offer for sale
- Fresh issue
- 0 shares
- Offer for sale
- 61,74,051 shares (₹655.37 Cr)
- Total issue
- 61,74,051 shares (₹655.37 Cr)
- Face value
- ₹10
- Listing at
- NSE, BSE
- Promoter holding
- 72.50% → 69.00%
Source: ProspectusUpdated
Reservation
Share of the total issue- Retail34.7%
- Anchor29.7%
- QIB ex-anchor19.8%
- Big NII9.9%
- Small NII5.0%
- Employees0.9%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | 21,40,606 | 34.67% | 35% |
| Non-institutional investors (NII) | 9,17,403 | 14.86% | 15% |
| Small NII (₹2–10 lakh) | 3,05,801 | 4.95% | — |
| Big NII (above ₹10 lakh) | 6,11,602 | 9.91% | — |
| Qualified institutional buyers (QIB) | 30,58,007 | 49.53% | 50% |
| QIB, excluding anchor | 12,23,203 | 19.81% | — |
| Anchor investors | 18,34,804 | 29.72% | — |
| Employees | 58,035 | 0.94% | — |
Source: ProspectusUpdated
Lot size
Amounts at ₹1,062 per share| Category | Lots | Shares | Amount |
|---|---|---|---|
| Employees | 1 | 14 | ₹14,868 |
| Retail individual investors | 1 | 14 | ₹14,868 |
Source: ProspectusUpdated
Special quotas
- Employees
- ₹54 discount per share
Source: ProspectusUpdated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2025, pre-issue- EPS (basic)
- ₹24.43
- EPS (basic) (Weighted average)
- ₹19.58
- P/E (FY 2025 at floor price)
- 41.26×
- P/E (FY 2025 at cap price)
- 43.47×
- RoNW
- 24.65%
- RoNW (Weighted average)
- 22.07%
- ROCE
- 41.32%
- NAV per share (As on June 30, 2025)
- ₹99.25
- EBITDA margin
- 20.55%
- PAT margin
- 12.49%
Source: ProspectusUpdated
Financials
Consolidated, restated · ₹ crore| Period ended | 30 Jun 20253 months | 31 Mar 2025FY 2025 | 31 Mar 2024FY 2024 | 31 Mar 2023FY 2023 |
|---|---|---|---|---|
| Revenue from operations | 346.54 | 1,196.42 | 1,014.47 | 884.05 |
| Total income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| Profit after tax | 46.20 | 149.43 | 90.50 | 84.93 |
| Net worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
FY 2025 vs FY 2024: revenue +17.9%, profit after tax +65.1%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: ProspectusUpdated
About the company
The company is an India-focused branded pharmaceutical formulation firm that develops, manufactures and markets products across women's healthcare, cardio-diabeto, pain management, urology and other therapy areas. It sells a portfolio of 71 brands, with a core group of 27 'engine' brands driving most domestic sales. It operates two manufacturing facilities and supports its sales through a pan-India field force.
- Incorporated
- 2004
- Industry
- Pharmaceuticals
- Sector
- Healthcare and Pharma
- CIN
- U24231GJ2004PLC044656
- Website
- coronaremedies.com
Source: ProspectusUpdated
Promoters and shareholders
| Name | Type | Before issue | After issue | Shares offered |
|---|---|---|---|---|
| Dr. Kirtikumar Laxmidas Mehta | Promoter | 22.00% | 20.00% | 12,23,193 |
| Niravkumar Kirtikumar Mehta | Promoter | 22.00% | 22.00% | 0 |
| Ankur Kirtikumar Mehta | Promoter | 22.00% | 22.00% | 0 |
| Minaxi Kirtikumar Mehta | Promoter group | 2.18% | 1.00% | 7,21,691 |
| Dipabahen Niravkumar Mehta | Promoter group | 2.16% | 2.00% | 97,853 |
| Brinda Ankur Mehta | Promoter group | 2.16% | 2.00% | 97,853 |
| Sepia Investments Limited | Selling shareholder | 25.99% | 19.76% | 38,11,613 |
| Anchor Partners | Selling shareholder | 0.97% | 0.74% | 1,42,488 |
| Sage Investment Trust | Selling shareholder | 0.54% | 0.41% | 79,360 |
Source: ProspectusUpdated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Offer for sale by the selling shareholders; the company receives no proceeds from the offer | 655.37 |
| Achieving the benefits of listing, including visibility and liquidity for existing shareholders | Set with price |
Source: ProspectusUpdated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| CORONA Remedies LimitedIssuer | ₹24.43 | — | 24.65% | ₹99.14 |
| Abbott India Limited | ₹665.62 | 45.17× | 33.41% | ₹1,992.14 |
| Alkem Laboratories Limited | ₹181.11 | 31.39× | 18.07% | ₹1,002.37 |
| Eris Lifesciences Limited | ₹25.85 | 61.81× | 12.21% | ₹209.73 |
| GlaxoSmithKline Pharmaceuticals Limited | ₹54.76 | 46.87× | 47.54% | ₹115.19 |
| J.B. Chemicals & Pharmaceuticals Limited | ₹42.45 | 42.60× | 19.21% | ₹220.88 |
| Mankind Pharma Limited | ₹49.28 | 45.77× | 13.89% | ₹352.51 |
| Pfizer Limited | ₹167.79 | 29.63× | 18.20% | ₹921.88 |
| Sanofi India Limited | ₹179.46 | 24.47× | 48.05% | ₹373.68 |
| Torrent Pharmaceuticals Limited | ₹56.47 | 65.91× | 25.18% | ₹224.28 |
Source: ProspectusUpdated
Strengths and risks
Our summary of what the offer document statesStrengths
- Ranked among the faster-growing companies in the Indian pharmaceutical market by domestic sales growth between MAT June 2022 and MAT June 2025.
- A diversified portfolio of 71 brands, with 27 engine brands contributing about 72% of domestic sales in MAT June 2025.
- Pan-India sales network with a field force of 2,671 medical representatives focused on specialist doctors.
- Two manufacturing facilities and two R&D facilities registered with the Department of Scientific and Industrial Research.
- Experienced promoter-led management team, with support from a private equity investor.
Risks
- Women's healthcare, cardio-diabeto and pain management make up a large share of revenue, so weakness in these areas would hurt results.
- A large part of domestic sales comes from a small set of engine brands, mainly B-29 and Myoril.
- Almost all revenue comes from India, and international expansion is not yet established.
- Dependence on third-party suppliers without long-term contracts, including a group company for certain APIs.
- The company receives no proceeds from the offer, and its trademark and licence positions carry uncertainty.
Source: ProspectusUpdated
Documents
Contacts
Source: ProspectusUpdated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Demat credit
- Listing
Source: ProspectusUpdated
After listing
Listing price, day-one high and low, and the change from the issue price (₹1,062) appear here after the shares list on NSE and BSE.
Work out the gain or loss on allotted shares after charges and tax →
Frequently asked questions
When does the CORONA Remedies IPO open and close?
According to the Prospectus, the issue opens on Monday, 8 December 2025 and closes on Wednesday, 10 December 2025.
What is the CORONA Remedies IPO price band?
The final issue price is ₹1,062 per share.
What is the lot size of the CORONA Remedies IPO?
One lot is 14 shares, which is ₹14,868 at ₹1,062 per share.
Where will CORONA Remedies shares list?
On NSE and BSE. The tentative listing date is Monday, 15 December 2025.
Who is the registrar of the issue?
Bigshare Services Private Limited (SEBI registration INR000001385). Allotment status is checked on the registrar's website.
How do I check the CORONA Remedies IPO allotment status?
Search by PAN, application number or DP/client ID on the registrar's website (Bigshare Services Private Limited), the NSE website or the BSE website. Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹655.37 Cr for offer for sale by the selling shareholders; the company receives no proceeds from the offer, and the rest for the other stated purposes.
Related IPOs
Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.